Applied Neurosolutions provides update regarding its blood-based Alzheimer’s test

Oct 9 2009

Applied NeuroSolutions, Inc. (OTCBB:APSN)(www.AppliedNeuroSolutions.com), a biotechnology company focused on the development of products for the early diagnosis and treatment of Alzheimer's disease ("AD"), today confirmed, as previously disclosed in July 2009, that it has achieved sufficient analytical sensitivity to detect tau in serum patient samples. This is a key step in the development of a blood-based test to detect AD at an early stage. Based on a further analysis of the preliminary data, the Company believes additional development of the assay, including optimization and validation in key patient population groups, is necessary to determine the specific sensitivity and specificity performance of the assay. The Company is currently raising funds to support continued development and commercialization of this blood-based Alzheimer’s test.

Applied NeuroSolutions, Inc. also announces the Company website has been updated, including a current Corporate Presentation.